Lapatinib-Capecitabine Versus Capecitabine Alone as Radiosensitizers in RAS Wild-Type Resectable Rectal Cancer, an Adaptive Randomized Phase II Trial (LaRRC Trial): Study Protocol for a Randomized Controlled Trial

Trials - United Kingdom
doi 10.1186/s13063-016-1583-y
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC


Related search